Table 3.

Clinical trials involving the combination of anti-angiogenic agents and immunotherapy.

Immune Checkpoint blockade + anti-angiogenic agents
Clinical trial	Condition	Phase	Intervention
NCT02348008	CCmRC	Phase I/II	Pembrolizumab+Bevacizumab
NCT02014636	CCmRC	Phase I	Pazopanib Pembrolizumab Pembrolizumab+Pazopanib
NCT01472081	CCmRC	Phase I	Nivolumab+Ipilimumab Nivolumab+Pazopanib Nivolumab+ Sunitinib
NCT02337491	Glioblastoma	Phase II	Pembrolizumab Pembrolizumab+Bevecizumab
NCT02501096	Solid tumors	Phase I/II	Pembrolizumab+Lenvatinib

CCmRC = clear cell metastatic renal cancer;